*3.2.1 Step 1: selection of non-price criteria*

At the beginning of the interactive part of the workshop, the participants discussed and selected the most important non-price criteria which should be considered for determining the value of multisource pharmaceuticals starting from the set of criteria resulting from the pre-workshop preparation. During this discussion, several alterations were adopted so that it finally resulted in 10 non-price selection criteria, of which:


#### **Table 1.**

*List of criteria with consensus scoring (qualitative descriptive) (Part 1).*


Two other criteria have been considered but were not adopted to the final essential list of decision criteria: The Certificate of Analysis for the API was considered a prerequisite to enter the bidding and, therefore, would not be relevant for further differentiation between the products; pharmacovigilance was also not considered relevant for the multisource pharmaceuticals used in the hospital setting. In addition, it was warned that this criterion might introduce an unfair bias toward the originator products who are usually the only ones pursuing a pharmacovigilance database on the national or international level.


**Table 2.**

*List of criteria with consensus scoring (qualitative descriptive) (Part 2).*

*Weighing Price and Performance for Decisions for Multisource Pharmaceutical Bidding in Public… DOI: http://dx.doi.org/10.5772/intechopen.83823*
